Last week, JPMorgan kicked off banking earnings with a quarter that was better than what many feared, and the entire group jumped on the news.
Since then, all of the major financials have also reported: Goldman Sachs, Bank of America, Wells Fargo, Citigroup and Morgan Stanley.
"Any way you slice it, this was a rough quarter for the banks, but none of them denied it. They did not apologize and they did not make excuses," Cramer said.
Ultimately, Cramer expects the banking cohort to head higher, especially now that investment banking divisions seem to be improving. The group has been scorned for years, and now it is their time to shine.
After a hideous sell-off in biotech this year, the group has started to finally rebound. One of those stocks is BioMarin, one of the leading makers of orphan drugs that treat rare diseases.
BioMarin has multiple drugs on the market, including three for rare metabolic disorders, one for phenylketonuria and a recently approved drug for duchenne muscular dystrophy. Additionally, it just released strong data on a hemophilia drug and a treatment for a common form of dwarfism.
Cramer spoke with BioMarin's CEO Jean-Jacques Bienaimé, who confirmed the encouraging results found in its early-stage hemophilia therapy.
"The results are definitely above our expectations, and above most key experts in the field expectations," Bienaimé said
In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:
KKR & Co: "We need a better IPO market so they can bring public some of the stocks that they have, and I think we are going to get it. So, therefore I think buy."
Fiesta Restaurant: "They seem to have lost a little bit of momentum. The stock is a little bit high in price. Let's listen to what Yum has to say tomorrow. You know I think that one is good, I said buy a little before and maybe buy some after."
Read MoreCramer: The stock to buy when IPOs heat up